Guy Marie FRANCOIS
Brussels, Belgium
NCT Number: NCT03415529
There appears to be considerable variability in the approach physicians use to manage arterial carbon dioxide tensions, in patients in the early phases [first 48 hours] of ARDS (Acute hypoxemic respiratory failure and). A number of specific concerns exist, particularly the use of greater than needed inspired oxygen concentrations (potentially in 40% patients), and the proportion of hypocapnic patients in our cohort.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Brussels, Belgium
This study will address a number of specific concerns, including:
LUNG SAFE was a prospective observational study. There was not patient intervention. The current analysis is a secondary analysis of this existing database.
Data will be abstracted form the database on all patients meeting the inclusion criteria for ARDS (during the first 2 days from AHRF onset) for the following variables: Patient's demographic characteristics (age, sex) and chronic comorbidities, Arterial PCO2, pH in first 48 hours, Data on P/F ratio over course of illness, Duration of ventilation, ICU stay, hospital survival in patients identified as being exposed to hypocapnia (pCO2 < or = to 30mmHg) and hypercapnia (PCO2 > or = to 45mmHg); Main ventilatory variables: mode of ventilation, tidal volume, respiratory.
Descriptive statistics will include proportions for categorical and mean (standard deviation) or median (interquartile range) for continuous variables, according the data distribution. The amount of missing data in the LUNG SAFE database is low so no assumptions will be made for missing data.
In order to investigate the relationship between PaCO2 and management factors, the investigators will stratify study population according the presence or absence of hypercapnia and will evaluate differences in management factors, using appropriate statistical tests. In detail, proportions will be compared using chi-squared or Fisher exact tests and mean values were compared using T-test or Wilcoxon rank sum test, as appropriate. Shapiro-Wilks test will be used to assess normality in data distribution. Moreover, they will perform univariate and multivariable logistic regression models using hypercapnia as dependent variable. Stepwise regression approach with significance alpha levels of 0.05 (both for entry and retention) will be used to establish a set of independent predictors. Odds ratios (ORs) and 95% confidence intervals (CIs) will be reported as measure of association.
They will assess the association of hypercapnia with different outcomes (ARDS progression, duration of mechanical ventilation, ICU and hospital stay and mortality) using generalized linear regression models (Poisson or Logistic regression models, according outcome distribution) and adjusting the relationship with all possible confounders identified with stepwise approach. Results will be reported as ORs, incidence rate ratios and corresponding 95% CI.
Particular attention will be given to the relationship and interaction between pH and PaCO2.
Survival analysis (Kaplan-Meier approach) will be used to estimate the time of liberation from invasive mechanical ventilation, of ICU and hospital discharge, and of hospital mortality within 28 days of AHRF onset in patients with and without hypercapnia. Differences in survival time will be assess by Log-Rank test.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: LUNG SAFE was a prospective observational study. Patients were followed until hospital discharge or day 90, whichever came first
The incidence of hypercapnia [i.e. PaCO2 > 45 mmHg] when ARDS arises
Time frame: LUNG SAFE was a prospective observational study. Patients were followed until hospital discharge or day 90, whichever came first
The severity of hypercapnia [i.e. PaCO2 > 45 mmHg] when ARDS arises ARDS
Time frame: LUNG SAFE was a prospective observational study. Patients were followed until hospital discharge or day 90, whichever came first
Factors (e.g. ventilatory mode) contributing to hypercapnia in patients with ARDS
Time frame: LUNG SAFE was a prospective observational study. Patients were followed until hospital discharge or day 90, whichever came first
The impact of hypercapnia on outcome on the progression of ARDS
Time frame: LUNG SAFE was a prospective observational study. Patients were followed until hospital discharge or day 90, whichever came first
The impact of pH (respiratory versus metabolic cause) on outcome variables
European Society of Intensive Care Medicine
Other
Incidence of Hypercapnia and Impact of Arterial CO2 Tension on Management and Outcome in Patients With Acute Respiratory Distress Syndrome (ARDS)
Acronym: CO2 LUNG SAFE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02010073
Acute Respiratory Distress Syndrome, Acute Severe Respiratory Failure
Brussels, Belgium
View Trial DetailsNCT03255109
Acute Respiratory Distress Syndrome, Acute Severe Respiratory Failure
Brussels, Belgium
View Trial DetailsNCT05930418
Acute Respiratory Distress Syndrome, Cardiovascular Diseases
Memphis, Tennessee, United States
View Trial DetailsNCT01438853
Acute Lung Injury, Acute Respiratory Distress Syndrome
Miami, Florida, United States
View Trial Details